SE
1
Active Trials
7
Total Trials
1
Organizations
1
Events
Sweden
Medical Only (Private)
Reimbursed Care Access
Sweden maintains a restrictive narcotics framework: classical and novel psychedelics (psilocybin, MDMA, DMT, mescaline and most tryptamines) are controlled and have no routine medical/reimbursed use outside approved clinical research. Esketamine (Spravato) is authorised in the EU and has been the subject of Swedish health-economics assessment; access is limited to specialist psychiatry with supervised administration and regional/clinic-level funding decisions. Ketamine is an authorised anaesthetic and used in Swedish clinical research and some specialised/privately delivered off‑label psychiatric protocols, but routine outpatient ketamine infusion therapy for psychiatric indications is not a standard, nationally reimbursed service.